Preliminary experience with 68Ga-DOTA-lanreotide positron emission tomography

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 52-60

  Traub Weidinger, T ^a   Von Guggenberg, E ^a   Dobrozemsky, G ^a   Kendler, D ^a   Eisterer, W ^b   Bale, R ^a   Putzer, D ^a   Gabriel, M ^a   Virgolini, I ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Lanreotide; Possitron emission tomography; Somatostatin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE GA 68; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; BONE METASTASIS; BONE TUMOR; BRAIN METASTASIS; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DYNAMICS; EQUIPMENT; EXPERIENCE; HUMAN; IMAGE RECONSTRUCTION; INJECTION; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RADIOACTIVITY; RECORDING; THYROID MEDULLARY CARCINOMA; TUMOR RECURRENCE; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; AMINO ACID SEQUENCE; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 77952510479     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 111In-DOTA-DPhe1) and (123I-Tyr3)-octreotide: the Rotterdam experience with more than 1000 patients. EurJ Nucl Med 1993;18:1-16.
2. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-58
3. Virgolini I, Traub T, Novotny C, Leimer M, Fueger B, Li SR et al. Experience with 111In-and 90Y-labeled somatostatin analogs. Current Pharmaceutical Design 2002;8:1781-1807
4. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46(Suppl 1):172-178
5. Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B et al. Cross competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994;54:690-700.
6. 99mTc-EDDA/HYNIC-Tyr3-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 2005;49:237-244
7. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136-5148
8. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E et al. 111In-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928-1936
9. Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18FFDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144-1151
10. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-155
11. Reubi JC, Schaer JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SSt5 of somatostatinradiotracer selected for scintigraphic and radiothaerpeutic and radio therapeutic use. Eur J Nucl Med 2000;27:273-282
12. Virgolini I, Traub T, Novotny C, Leimer M, Fueger B, Li SR et al. New trends in peptide receptor radioligands. Q J Nucl Med. 2001;45:153-159
13. Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2006;33:532-540
14. Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fuegger BJ et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001;42:1309-1315
15. 68Ga-DOTATOC: preliminray data. Eur J Nucl Med 2001;28:1751-1757
16. 68Gallium: a carrier effect. J Nucl Med 1965;6:605-610
17. 68Gallium as a scanning agent for intracranial lesions. J Nucl Med 1964;5:161-167
18. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008;3:67-77.
19. 68Ga- labelled peptides. Nucl Med Commun 2007;28:870-875
20. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518
21. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-1434
22. 68Ga-DOTA- Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-1221
23. 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilization device with external markers in patients with endocrine tumors. Eur J Nucl Med Mol Imaging 2005;32:1440-1451
24. Virgolini IJ, Gabriel M, von Guggenberg E, Putzer D, Kendler D, Decristoforo C. Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumors. Eur J Cancer 2009;45(Suppl 1):274-291
25. 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-485
26. 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008;35:1507-1515
27. Heppeler A, Froidevaux S, Macke HR, Jermann E, Behe M, Powell P et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974-1981
28. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-993
29. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Froidevaux Int J Cancer 2002;20:930-937
30. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282